Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial

Trial Profile

Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs T-lymphocyte cell therapy (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TC BioPharm
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 10 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 09 Sep 2015 Planned initiation date changed from 1 Sep 2015 to 1 Oct 2015, as reported by a TC BioPharm media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top